Effect of HPV Vaccination on Virus Disappearance in Cervical Samples of a Cohort of HPV-Positive Polish Patients

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Dec 23

PMID 38137661

Authors

Dominik Pruski

Sonja Millert-Kalinska

Malgorzata Lagiedo

Jan Sikora

Robert Jach

Marcin Przybylski

Affiliations

Soon will be listed here.

Abstract

The introduction of human papillomavirus vaccines revolutionized cervical cancer prevention. Our research hypothesis is that HPV vaccination affects the remission of HPV in cervical swabs. We provide a prospective, ongoing, 24-month, non-randomized study in HPV-positive women. We enrolled 60 patients with positive HPV swabs from the cervix (fifty-one vaccinated with the nine-valent vaccine against HPV and nine unvaccinated). Using an enzyme-linked immunosorbent assay, we determined IgG class antibodies of HPV in the patients' serums. Persistent HPV infection after vaccination was significantly less frequent in the nine-valent vaccinated group (23.5%) compared to the control group (88.9%; < 0.001). Antibody level after vaccination was significantly higher in the vaccinated patients compared to the control group. The reactive antibody level was seen in the case of all patients in the vaccinated group and one-third of the unvaccinated group (33.3%, n = 3). The vaccination of HPV-positive patients may increase the chance of HPV remission in cervical swabs and may be a worthwhile element of secondary prevention in HPV-positive patients.

Citing Articles

Evaluation of the Use of Methylation as a New Tool for the Diagnostics and Progression of Squamous Intraepithelial Lesions.

Pruski D, Millert-Kalinska S, Lis A, Pelc E, Konopelski P, Jach R Int J Mol Sci. 2024; 25(22).

PMID: 39595932 PMC: 11594127. DOI: 10.3390/ijms252211863.

Risks of Cervical Cancer Recurrence After Fertility-Sparing Surgery and the Role of Human Papillomavirus Infection Types.

Aimagambetova G, Bapayeva G, Ukybassova T, Kamzayeva N, Sakhipova G, Shanazarov N J Clin Med. 2024; 13(21).

PMID: 39518458 PMC: 11547075. DOI: 10.3390/jcm13216318.

Evaluation of Automatic Signal Detection of In Situ Hybridization for Detecting HPV DNA in Cervical Tissue Derived from Patients with Cervical Intraepithelial Neoplasia.

Przybylski M, Millert-Kalinska S, de Mezer M, Krzyzaniak M, Kurzawa P, Zurawski J Cancers (Basel). 2024; 16(20).

PMID: 39456579 PMC: 11506503. DOI: 10.3390/cancers16203485.

Prevalence and Description of High-Grade Intraepithelial Lesions of Cervical Mucosa Cells in a Screening Programme for Cervical Cancer in Isère, France.

Balamou C, Zysman K, Olicard C, Garnier A, Seigneurin A Cancer Med. 2024; 13(19):e70259.

PMID: 39400464 PMC: 11472336. DOI: 10.1002/cam4.70259.

Prevalence of human papillomavirus and cervical lesions among elderly women: an unignored challenge to cervical cancer prevention.

Huiyun J, Yuebo Y, Xiaomao L Ann Med. 2024; 56(1):2404548.

PMID: 39298375 PMC: 11413955. DOI: 10.1080/07853890.2024.2404548.

References

Harper D, DeMars L . HPV vaccines - A review of the first decade. Gynecol Oncol. 2017; 146(1):196-204. DOI: 10.1016/j.ygyno.2017.04.004. View

Crosbie E, Kitchener H . Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther. 2007; 7(3):391-6. DOI: 10.1517/14712598.7.3.391. View

Giuliano A, Palefsky J, Goldstone S, Moreira Jr E, Penny M, Aranda C . Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364(5):401-11. PMC: 3495065. DOI: 10.1056/NEJMoa0909537. View

Hildesheim A, Herrero R, Wacholder S, Rodriguez A, Solomon D, Bratti M . Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298(7):743-53. DOI: 10.1001/jama.298.7.743. View

Valasoulis G, Pouliakis A, Michail G, Kottaridi C, Spathis A, Kyrgiou M . Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women. Cancers (Basel). 2020; 12(5). PMC: 7281708. DOI: 10.3390/cancers12051164. View

Arbyn M, Redman C, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S . Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017; 18(12):1665-1679. DOI: 10.1016/S1470-2045(17)30700-3. View

Sand F, Kjaer S, Frederiksen K, Dehlendorff C . Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2019; 147(3):641-647. DOI: 10.1002/ijc.32752. View

Nayar R, Chhieng D, Crothers B, Darragh T, Davey D, Eisenhut C . Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. J Am Soc Cytopathol. 2020; 9(4):291-303. DOI: 10.1016/j.jasc.2020.05.002. View

Hall M, Smith M, Lew J, OHallahan J, Fentiman G, Neal H . The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. Gynecol Oncol. 2019; 152(3):472-479. DOI: 10.1016/j.ygyno.2018.10.045. View

10.

Pruski D, Fraszczak J, Iwaniec K, Przybylski M, Kedzia W, Gretkiewicz-Tomczyk A . Assessment of frequency of regression and progression of mild cervical neoplasia--LGSIL in women with positive high-risk HPV DNA test result. Ginekol Pol. 2013; 83(8):572-5. View

11.

Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J . Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front Cell Infect Microbiol. 2022; 12:909223. PMC: 9289603. DOI: 10.3389/fcimb.2022.909223. View

12.

Ghelardi A, Marrai R, Bogani G, Sopracordevole F, Bay P, Tonetti A . Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease. Vaccines (Basel). 2021; 9(2). PMC: 7911252. DOI: 10.3390/vaccines9020083. View

13.

Smith M, Hall M, Lew J, Canfell K . Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. Vaccine. 2018; 36(42):6314-6324. DOI: 10.1016/j.vaccine.2018.08.063. View

14.

Patel C, Brotherton J, Pillsbury A, Jayasinghe S, Donovan B, Macartney K . The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?. Euro Surveill. 2018; 23(41). PMC: 6194907. DOI: 10.2807/1560-7917.ES.2018.23.41.1700737. View

15.

Ciccarese G, Herzum A, Rebora A, Drago F . Prevalence of genital, oral, and anal HPV infection among STI patients in Italy. J Med Virol. 2016; 89(6):1121-1124. DOI: 10.1002/jmv.24746. View

16.

Hagensee M, Yaegashi N, Galloway D . Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993; 67(1):315-22. PMC: 237365. DOI: 10.1128/JVI.67.1.315-322.1993. View

17.

Fogleman C, Leaman L . Prophylactic Vaccination Against Human Papillomavirus to Prevent Cervical Cancer and Its Precursors. Am Fam Physician. 2019; 99(1):15-16. View

18.

Garland S, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow S . Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer. 2016; 139(12):2812-2826. PMC: 5412942. DOI: 10.1002/ijc.30391. View

19.

Przybylski M, Pruski D, Wszolek K, de Mezer M, Zurawski J, Jach R . Prevalence of HPV and Assessing Type-Specific HPV Testing in Cervical High-Grade Squamous Intraepithelial Lesions in Poland. Pathogens. 2023; 12(2). PMC: 9963087. DOI: 10.3390/pathogens12020350. View

20.

Bissett S, Godi A, Jit M, Beddows S . Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine. 2017; 35(32):3922-3929. DOI: 10.1016/j.vaccine.2017.06.028. View